Genenta Science S.p.A.
GNTA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001838716
No open-market purchases or sales by Genenta Science S.p.A. insiders were filed in the last 90 days; 9 institutions reported holding it in 13F filings for Q2 2026, worth $1.33M in total; no superinvestor holds it.
13F holders, Q1 2026
Institutional positions in Genenta Science S.p.A. as of Mar 31, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 11
- −3 vs. Q4 2025
- Shares held
- 1.04M
- −1.45M (−58.4%) vs. Q4 2025
- Total value
- $695.7K
- −$3.01M (−81.2%) vs. Q4 2025
- New holders
- 3
- 2 more added
- Sold out
- 6
- 2 more reduced
1 institution that held it in Q4 2025 haven't filed for Q1 2026 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q4 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting GNTA on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 9 | $1.33M |
| Q1 2026 | 11 | $695.7K |
| Q4 2025 | 15 | $4.04M |
| Q3 2025 | 6 | $1.77M |
| Q2 2025 | 5 | $1.82M |
| Q1 2025 | 5 | $2.10M |
| Q4 2024 | 4 | $1.42M |
| Q3 2024 | 5 | $1.48M |
| Q2 2024 | 5 | $1.04M |
| Q1 2024 | 5 | $1.92M |
| Q4 2023 | 4 | $3.67M |
| Q3 2023 | 3 | $2.29M |
| Q2 2023 | 4 | $2.73M |
| Q1 2023 | 2 | $273.8K |
| Q4 2022 | 4 | $264.4K |
| Q3 2022 | 2 | $17.0K |
| Q2 2022 | 3 | $27.0K |
| Q1 2022 | 3 | $332.0K |
| Q4 2021 | 2 | $517.0K |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q1 2026
Shares, value and share of portfolio for each institution holding Genenta Science S.p.A.; share changes are against Q4 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Eurizon Capital SGR S.p.A. | 360,000 | $241.9K | 0.00% | 00.0% | Unchanged |
| Allianz SE | 234,050 | $157.3K | 0.00% | 00.0% | Unchanged |
| AlTi Global, Inc. | 200,288 | $134.6K | 0.00% | 00.0% | Unchanged |
| SmartHarvest Portfolios, LLC | 134,447 | $90.3K | 0.04% | +116,666+656.1% | Added |
| Independent Advisor Alliance | 37,036 | $24.9K | 0.00% | +37,036 | New |
| XTX Topco Ltd | 24,527 | $16.5K | 0.00% | +24,527 | New |
| Morgan Stanley | 15,420 | $10.4K | 0.00% | −30,480−66.4% | Reduced |
| GAMMA Investing LLC | 14,288 | $9.60K | 0.00% | +11,461+405.4% | Added |
| Simplicity Wealth,LLC | 12,211 | $8.21K | 0.00% | +12,211 | New |
| UBS Group AG | 3,107 | $2.09K | 0.00% | −309−9.0% | Reduced |
| Farther Finance Advisors, LLC | 3 | $2 | 0.00% | 00.0% | Unchanged |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −655,164−100.0% | Sold out |
| Ghisallo Capital Management LLC | 0 | $0 | 0.00% | −323,797−100.0% | Sold out |
| Weiss Asset Management LP | 0 | $0 | 0.00% | −322,026−100.0% | Sold out |
| Alyeska Investment Group, L.P. | 0 | $0 | 0.00% | −219,838−100.0% | Sold out |
| Algebris (UK) Ltd | 0 | $0 | 0.00% | −100,000−100.0% | Sold out |
| National Bank of Canada | 0 | $0 | 0.00% | −2,668−100.0% | Sold out |
| Norges Bank | – | – | – | – | Not filed |